- Home
- FNKO vs CGTX Comparison
FNKO vs CGTX Comparison
Compare FNKO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNKO
- CGTX
- Stock Information
- Founded
- FNKO 2017
- CGTX 2007
- Country
- FNKO United States
- CGTX United States
- Employees
- FNKO N/A
- CGTX N/A
- Industry
- FNKO Recreational Games/Products/Toys
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FNKO Consumer Discretionary
- CGTX Health Care
- Exchange
- FNKO Nasdaq
- CGTX Nasdaq
- Market Cap
- FNKO 170.7M
- CGTX 158.8M
- IPO Year
- FNKO 2017
- CGTX 2021
- Fundamental
- Price
- FNKO $3.06
- CGTX $1.76
- Analyst Decision
- FNKO Buy
- CGTX Strong Buy
- Analyst Count
- FNKO 4
- CGTX 3
- Target Price
- FNKO $7.13
- CGTX $2.83
- AVG Volume (30 Days)
- FNKO 783.3K
- CGTX 1.4M
- Earning Date
- FNKO 11-06-2025
- CGTX 11-07-2025
- Dividend Yield
- FNKO N/A
- CGTX N/A
- EPS Growth
- FNKO N/A
- CGTX N/A
- EPS
- FNKO N/A
- CGTX N/A
- Revenue
- FNKO $970,702,000.00
- CGTX N/A
- Revenue This Year
- FNKO N/A
- CGTX N/A
- Revenue Next Year
- FNKO $10.57
- CGTX N/A
- P/E Ratio
- FNKO N/A
- CGTX N/A
- Revenue Growth
- FNKO N/A
- CGTX N/A
- 52 Week Low
- FNKO $2.22
- CGTX $0.22
- 52 Week High
- FNKO $14.65
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- FNKO 45.44
- CGTX 52.38
- Support Level
- FNKO $2.93
- CGTX $1.54
- Resistance Level
- FNKO $3.18
- CGTX $1.83
- Average True Range (ATR)
- FNKO 0.16
- CGTX 0.14
- MACD
- FNKO 0.01
- CGTX -0.00
- Stochastic Oscillator
- FNKO 36.19
- CGTX 52.50
About FNKO Funko Inc.
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.